Physician profile
Patrick C Lee
NPI 1356442602
$2,223.51
in general payments reported to CMS, 2019-2025
32 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $337 · 2021: $368 · 2022: $130 · 2023: $65.94 · 2024: $272 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $249.26 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $201.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $173.25 | 2019-2021 | |
| Amgen INC. | $171.10 | 2019-2020 | |
| Janssen Biotech, INC. | $165.83 | 2019-2024 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $152.18 | 2019-2024 | Krazati |
| Daiichi Sankyo INC. | $132.97 | 2020-2025 | Vanflyta, Injectafer |
| Celgene Corporation | $130.00 | 2019-2024 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $97.64 | 2019-2023 | |
| Incyte Corporation | $77.99 | 2021 | |
| Genzyme Corporation | $77.37 | 2019-2025 | |
| Abbvie INC. | $70.13 | 2019-2024 | |
| Eisai INC. | $68.82 | 2019-2021 | |
| Genentech USA, INC. | $68.23 | 2019-2020 | |
| Lilly USA, LLC | $66.17 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.68 | 2019-2020 | |
| Puma Biotechnology, INC. | $29.26 | 2019-2021 | |
| Astellas Pharma US INC | $29.22 | 2019 | |
| Kyowa Kirin, INC. | $26.80 | 2019 | |
| Gilead Sciences, INC. | $25.18 | 2019-2021 | |
| Pfizer INC. | $21.20 | 2025 | |
| Novocure INC. | $19.85 | 2025 | Optune Gio |
| Dendreon Pharmaceuticals LLC | $15.64 | 2024 | Provenge |
| Taiho Oncology, INC. | $14.93 | 2019 | |
| Exelixis INC. | $14.80 | 2021 | |
| Kite Pharma, INC. | $14.45 | 2021 | |
| Eusa Pharma (US) LLC | $14.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.06 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $13.34 | 2021 | |
| Rigel Pharmaceuticals, INC. | $13.10 | 2019 | |
| Global Blood Therapeutics, INC. | $13.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.